Carla F.
- Country
- Portugal
- Department
- Neurology
Research Overview
- Efficacy and Safety Evaluation of JX10 in Acute Ischemic Stroke Patients with Delayed Presentation: A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study
- A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
Data & Insights
Has run more than one trial at 33 of 266 partner sites.
Specializations
Cerebrovascular Research
The investigator specializes in the study of acute ischemic stroke and high-risk transient ischemic attack, focusing on innovative therapeutic approaches for these critical neurological conditions.
- Stroke Prevention
- Cerebrovascular Disease Management
- Neurological Recovery
Clinical expertise centers on evaluating therapeutic interventions aimed at reducing the risk of ischemic events in patients with cerebrovascular conditions.
Therapeutic Focus
The investigator conducts research in antithrombotic therapy and stroke risk reduction, exploring new treatment options for patients who have experienced acute cerebrovascular events.
- Antithrombotic Interventions
- Secondary Stroke Prevention
- Risk Factor Management
Areas of investigation include novel therapeutic approaches for preventing recurrent ischemic events in high-risk patients.
Clinical Expertise
The investigator's work encompasses acute stroke management and the development of interventions for cerebrovascular disorders.
- Acute Stroke Care
- Neurological Assessment
- Treatment Optimization
Research activities focus on evaluating therapeutic efficacy in acute cerebrovascular conditions and improving patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.